Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Sichuan University
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06732258CT.gov Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC | — | Withdrawn | — | — | — |
NCT06648200CT.gov Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06256237CT.gov Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial | — | Recruiting | — | — | — |
NCT06095583CT.gov Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tifcemalimab (this asset) | Sichuan University | P3 | BB · 66 |
| Benmelstobart | Yayi He | P4 | A |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Nogitecan | AbbVie | P4 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Tifcemalimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 53 |
| Hodgkins Lymphoma | — | P3 | CCC · 52 |
| Triple-Negative Breast Carcinoma | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tifcemalimab in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tifcemalimab-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →